Literature DB >> 9867163

Absolute organ activity estimated by five different methods of background correction.

W C Buijs1, J A Siegel, O C Boerman, F H Corstens.   

Abstract

UNLABELLED: Accurate absorbed dose estimates in radionuclide therapy require patient-specific dosimetry. In patient-based dosimetry, estimation of absolute organ uptake is essential. The methods used should be reasonably accurate as well as easy to perform in routine clinical practice. One of the major sources of uncertainty in quantification of organ or tumor activity from planar images is the activity present in the tissue surrounding the source.
METHODS: To estimate organ activity as a function of organ-to-background activity concentration ratio, a cylindrical phantom, filled with 5.6 liters of water was used to simulate the abdomen of a patient. Two other cylinders of 150 ml each, representing the kidneys, were each filled with 19 MBq 99mTC and were positioned in the abdomen phantom. The phantom was imaged with a dual-head gamma camera with the kidneys placed at posterior depths of 1-, 5- and 10-cm at kidney-to-background activity concentration ratios of infinity, 10:1, 5:1 and 2:1. The conjugate view geometric mean counting method was used to quantify activity. Five methods for background correction were applied: (1) no correction; (2) conventional background correction (simple subtraction of the background counting rate from the source region counting rate); (3) Kojima method (background corrected for organ thickness and depth); (4) Thomas method (analytical solution); and (5) Buijs method (background corrected for organ and total-body thickness).
RESULTS: Since the results were identical for both kidneys, only the left kidney activity measurements are presented. The accuracy of the five background correction methods is given as the percentage difference between the actual and measured activity in the left kidney. For Method 1, the percentage difference ranged from 2% with an infinite kidney-to-background activity concentration ratio to +413% with a 2:1 ratio. For Method 2, these values ranged from -1% to -80%, for Method 3 from +11% to -18%, for Method 4 from -2% to +120% and for Method 5 from -4% to +39%.
CONCLUSION: Even though quantitative SPECT is the most rigorous method for activity quantification in conditions of low organ-to-background activity concentration ratio, planar scintigraphy can be applied accurately if appropriate attention is paid to background correction. Using relatively simple background subtraction methods, the quantitative planar imaging technique can result in reasonably accurate activity estimates (Methods 3 and 5). The use of Kojima's method is preferable, especially at very low source-to-background activity concentration ratios.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9867163

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  21 in total

1.  [(111)In]DOTATOC as a dosimetric substitute for kidney dosimetry during [(90)Y]DOTATOC therapy: results and evaluation of a combined gamma camera/probe approach.

Authors:  Alexander Stahl; Sylvia Schachoff; Ambros Beer; Anna Winter; Hans Jürgen Wester; Klemens Scheidhauer; Markus Schwaiger; Ingo Wolf
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-04-28       Impact factor: 9.236

2.  Software package for integrated data processing for internal dose assessment in nuclear medicine (SPRIND).

Authors:  Eric Visser; Ernst Postema; Otto Boerman; Jeroen Visschers; Wim Oyen; Frans Corstens
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-11-15       Impact factor: 9.236

3.  The potential of 223Ra and 18F-fluoride imaging to predict bone lesion response to treatment with 223Ra-dichloride in castration-resistant prostate cancer.

Authors:  Iain Murray; Sarah J Chittenden; Ana M Denis-Bacelar; Cecilia Hindorf; Christopher C Parker; Sue Chua; Glenn D Flux
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-06-13       Impact factor: 9.236

4.  EQPlanar: a maximum-likelihood method for accurate organ activity estimation from whole body planar projections.

Authors:  N Song; B He; R L Wahl; E C Frey
Journal:  Phys Med Biol       Date:  2011-08-03       Impact factor: 3.609

5.  Comparative evaluation of technetium-99m-diethylenetriaminepentaacetic acid renal dynamic imaging versus the Modification of Diet in Renal Disease equation and the Chronic Kidney Disease Epidemiology Collaboration equation for the estimation of GFR.

Authors:  Qi Huang; Yunshuang Chen; Min Zhang; Sihe Wang; Weiguang Zhang; Guangyan Cai; Xiangmei Chen; Xuefeng Sun
Journal:  Int Urol Nephrol       Date:  2018-02-20       Impact factor: 2.370

6.  Radioimmunotherapy with Tenarad, a 131I-labelled antibody fragment targeting the extra-domain A1 of tenascin-C, in patients with refractory Hodgkin's lymphoma.

Authors:  Luigi Aloj; Laura D'Ambrosio; Michela Aurilio; Anna Morisco; Ferdinando Frigeri; Corradina Caraco'; Francesca Di Gennaro; Gaetana Capobianco; Leonardo Giovannoni; Hans D Menssen; Dario Neri; Antonio Pinto; Secondo Lastoria
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-01-17       Impact factor: 9.236

7.  Estimates of radiation-absorbed dose to kidneys in patients treated with 90Y-ibritumomab tiuxetan.

Authors:  Sébastien Baechler; Robert F Hobbs; Andrew R Prideaux; Mélanie Recordon; Angelika Bischof-Delaloye; George Sgouros
Journal:  Cancer Biother Radiopharm       Date:  2008-10       Impact factor: 3.099

8.  Absorbed dose and biologically effective dose in patients with high-risk non-Hodgkin's lymphoma treated with high-activity myeloablative 90Y-ibritumomab tiuxetan (Zevalin).

Authors:  C Chiesa; F Botta; A Coliva; M Maccauro; L Devizzi; A Guidetti; C Carlo-Stella; E Seregni; M A Gianni; E Bombardieri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-05-20       Impact factor: 9.236

9.  A theoretical dose-escalation study based on biological effective dose in radioimmunotherapy with (90)Y-ibritumomab tiuxetan (Zevalin).

Authors:  Massimiliano Pacilio; Margherita Betti; Francesco Cicone; Carolina Del Mastro; Livia Montani; Laura Chiacchiararelli; Alessia Monaco; Enrico Santini; Francesco Scopinaro
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01-13       Impact factor: 9.236

10.  Dosimetry of bone metastases in targeted radionuclide therapy with alpha-emitting (223)Ra-dichloride.

Authors:  Massimiliano Pacilio; Guido Ventroni; Giuseppe De Vincentis; Bartolomeo Cassano; Rosanna Pellegrini; Elisabetta Di Castro; Viviana Frantellizzi; Giulia Anna Follacchio; Tatiana Garkavaya; Leda Lorenzon; Pasquale Ialongo; Roberto Pani; Lucio Mango
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-08-13       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.